{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:47:26Z","timestamp":1791384446317,"version":"4.3.3"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart rate (HR) is associated with cardiovascular outcomes in all the stages of the cardiovascular continuum as well as in patients with pulmonary, cerebrovascular, and renal disease, sepsis, cancer, and erectile dysfunction. In patients with cardiovascular disease, but also in the general population, increased HR represents an important indicator of mortality with each acceleration of HR over 70 b.p.m. increasing the risk. In patients in sinus rhythm with chronic heart failure with reduced ejection fraction (HFrEF), a HR &amp;gt;70 b.p.m. increased the risk of hospitalization, and &amp;gt;75 b.p.m. the risk of cardiovascular death as shown in the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT). Reducing HR with ivabradine by 11 b.p.m. (placebo-controlled) reduced the primary composite endpoint (cardiovascular death and hospitalization for worsening heart failure). Ivabradine was well tolerated showing benefit irrespective of age or diabetes status, and also in the presence of low systolic blood pressure and severe heart failure (SHIFT trial). Therefore, HR qualifies as a modifiable risk factor in heart failure. In patients with stable coronary disease, HR is a risk marker but HR reduction with ivabradine does not improve outcomes. The role of selective HR lowering remains unclear in patients with pulmonary, renal, cerebrovascular, and other diseases, as the potential benefit of interventions on HR has not been explored in these conditions. Future studies should scrutinize if HR reduction improves outcomes, defining HR as a potential risk factor and therapeutic target in other conditions beyond heart failure.<\/jats:p>","DOI":"10.1002\/ejhf.902","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T04:53:29Z","timestamp":1497848009000},"page":"1230-1241","source":"Crossref","is-referenced-by-count":47,"title":["Heart Rate and its Reduction in Chronic Heart Failure and Beyond"],"prefix":"10.1093","volume":"19","author":[{"given":"Aleksandra","family":"Nikolovska Vukadinovi\u0107","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, der Universit\u00e4t des Saarlandes , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Vukadinovi\u0107","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, der Universit\u00e4t des Saarlandes , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Borer","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and the Howard Gilman Institute for Heart Valve Disease and the Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cowie","sequence":"additional","affiliation":[{"name":"Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Komajda","sequence":"additional","affiliation":[{"name":"University, La Piti\u00e9-Salp\u00e9tri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"Lainscak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Department of Research and Education , Celje ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, der Universit\u00e4t des Saarlandes , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"2026011721200231400_ejhf902-bib-0001","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.bjp.0707673","article-title":"Heart rate in the pathophysiology of coronary blood flow and myocardial ischemia: benefit from selective bradycardic agents","volume":"153","author":"Heusch","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2026011721200231400_ejhf902-bib-0002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00392-007-0537-5","article-title":"The role of heart rate in the development of cardiovascular disease","volume":"96","author":"Reil","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jjcc.2013.02.018","article-title":"A global target for cardiovascular disease and therapy along the cardiovascular disease continuum","volume":"62","author":"Custodis","year":"2013","journal-title":"J Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/heartjnl-2012-302301","article-title":"Heart rate: surrogate or target in the management of heart failure?","volume":"99","author":"B\u00f6hm","year":"2013","journal-title":"Heart"},{"key":"2026011721200231400_ejhf902-bib-0005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-venticular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2026011721200231400_ejhf902-bib-0006","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"2026011721200231400_ejhf902-bib-0007","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0008","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease","volume":"64","author":"DiFrancesco","year":"2004","journal-title":"Drugs"},{"key":"2026011721200231400_ejhf902-bib-0009","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/eurjhf\/hft129","article-title":"Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties","volume":"16","author":"Dobre","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0010","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers","volume":"64","author":"Ragueneau","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"2026011721200231400_ejhf902-bib-0011","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/107424840100600401","article-title":"Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate","volume":"6","author":"Singh","year":"2001","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026011721200231400_ejhf902-bib-0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0002-8703(91)90970-S","article-title":"Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study","volume":"121","author":"Gillum","year":"1991","journal-title":"Am Heart J"},{"key":"2026011721200231400_ejhf902-bib-0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.eurheartj.a062065","article-title":"The multifactor primary prevention trial in G\u00f6teborg, Sweden","volume":"7","author":"Wilhelmsen","year":"1986","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0014","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/oxfordjournals.aje.a113046","article-title":"Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies","volume":"112","author":"Dyer","year":"1980","journal-title":"Am J Epidemiol"},{"key":"2026011721200231400_ejhf902-bib-0015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: the Framingham Study","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"2026011721200231400_ejhf902-bib-0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ajh.2008.331","article-title":"Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population","volume":"22","author":"Shigetoh","year":"2009","journal-title":"Am J Hypertens"},{"key":"2026011721200231400_ejhf902-bib-0017","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2337\/dc07-0874","article-title":"Resting heart rate in middle age and diabetes development in older age","volume":"31","author":"Carnethon","year":"2008","journal-title":"Diabetes Care"},{"key":"2026011721200231400_ejhf902-bib-0018","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.1945.02860430001001","article-title":"Transcient tachycardia: prognostic significance alone and in association with transient hypertension","volume":"129","author":"Levy","year":"1945","journal-title":"JAMA"},{"key":"2026011721200231400_ejhf902-bib-0019","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1161\/01.CIR.90.6.2870","article-title":"Relation between physical training and ambulatory blood pressure in stage I hypertensive subjects. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia Study","volume":"90","author":"Palatini","year":"1994","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/HYPERTENSIONAHA.109.144808","article-title":"Resting heart rate pattern during follow-up and mortality in hypertensive patients","volume":"55","author":"Paul","year":"2010","journal-title":"Hypertension"},{"key":"2026011721200231400_ejhf902-bib-0021","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/hc3801.096325","article-title":"Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption","volume":"104","author":"Heidland","year":"2007","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0022","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jacc.2010.09.014","article-title":"Vascular pathophysiology in response to increased heart rate","volume":"56","author":"Custodis","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0023","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1161\/CIRCULATIONAHA.107.746537","article-title":"Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice","volume":"117","author":"Custodis","year":"2008","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0024","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000339547","article-title":"Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice","volume":"49","author":"Custodis","year":"2012","journal-title":"J Vasc Res"},{"key":"2026011721200231400_ejhf902-bib-0025","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1093\/eurheartj\/ehs218","article-title":"Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction","volume":"34","author":"Reil","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0026","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/ehs396","article-title":"Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography","volume":"34","author":"Hartaigh","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0027","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/eurjhf\/hfs195","article-title":"Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study","volume":"15","author":"Nanchen","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.113.01605","article-title":"Association of resting heart rate with carotid and aortic arterial stiffness: multi-ethnic study of atherosclerosis","volume":"62","author":"Whelton","year":"2013","journal-title":"Hypertension"},{"key":"2026011721200231400_ejhf902-bib-0029","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/heartjnl-2012-302795","article-title":"Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients","volume":"98","author":"Nerla","year":"2012","journal-title":"Heart"},{"key":"2026011721200231400_ejhf902-bib-0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00392-014-0679-1","article-title":"Ivabradine therapy to unmask heart rate-independent effects of \u03b2-blockers on pulse wave reflections","volume":"103","author":"Fischer-Rasokat","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0031","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2026011721200231400_ejhf902-bib-0032","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left venticular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0033","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721200231400_ejhf902-bib-0034","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/eurheartj\/ehv150","article-title":"The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY","volume":"36","author":"Ferrari","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0035","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehv190","article-title":"It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD?","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0036","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"2026011721200231400_ejhf902-bib-0037","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","article-title":"Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND","volume":"103","author":"Lonn","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0038","first-page":"267","article-title":"Procoralan: Antianginal efficacy through an innovative mode of action","volume":"28","author":"Elyubaeva","year":"2006","journal-title":"Medicographia"},{"key":"2026011721200231400_ejhf902-bib-0039","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0040","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0041","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","article-title":"Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial","volume":"67","author":"Ruzyllo","year":"2007","journal-title":"Drugs"},{"key":"2026011721200231400_ejhf902-bib-0042","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force Members","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0043","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrcardio.2016.84","article-title":"Heart rate reduction in coronary artery disease and heart failure","volume":"13","author":"Ferrari","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0044","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationship with bisoprolol benefit in chronic heart failure in CIBIS II Trial","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0045","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"2026011721200231400_ejhf902-bib-0046","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0047","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2004.10.032","article-title":"What resting heart rate should one aim for when treating patients with heart failure with beta blockers","volume":"45","author":"Gullestad","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0048","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026011721200231400_ejhf902-bib-0049","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026011721200231400_ejhf902-bib-0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"B\u00f6hm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0051","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"2026011721200231400_ejhf902-bib-0052","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/eurjhf\/hft032","article-title":"Risk following hospitalization in stable chronic systolic heart failure","volume":"15","author":"Abrahamsson","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0053","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0054","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ejhf.582","article-title":"Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ejhf.287","article-title":"A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE","volume":"17","author":"\u00c1lvarez-Garc\u00eda","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0056","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.amjcard.2013.10.033","article-title":"Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT Study)","volume":"113","author":"Borer","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0057","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00392-012-0436-2","article-title":"Lasting reduction of heart rate transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study","volume":"101","author":"Zhang","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0058","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000449243","article-title":"Efficacy profile of ivabradine in patients with heart failure plus angina pectoris","volume":"136","author":"Borer","year":"2016","journal-title":"Cardiology"},{"key":"2026011721200231400_ejhf902-bib-0059","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026011721200231400_ejhf902-bib-0060","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/eurheartj\/ehi386","article-title":"Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial","volume":"26","author":"Metra","year":"2005","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0061","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"B\u00f6hm","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0062","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ejhf.22","article-title":"Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study","volume":"16","author":"Takada","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0063","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ejhf.346","article-title":"Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis","volume":"17","author":"Simpson","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0064","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/eurheartj\/ehi166","article-title":"Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ejhf.674","article-title":"Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial","volume":"19","author":"Greene","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0066","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jchf.2014.01.005","article-title":"Is heart rate important for patients with heart failure in atrial fibrillation?","volume":"2","author":"Cullington","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0067","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"2026011721200231400_ejhf902-bib-0068","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10741-012-9315-1","article-title":"Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"2026011721200231400_ejhf902-bib-0069","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2012.11.004","article-title":"Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the efficacy of vasopresin antagonism in heart failure: outcome study with tolvaptan (EVEREST) trial","volume":"165","author":"Ambrosy","year":"2013","journal-title":"Am Heart J"},{"key":"2026011721200231400_ejhf902-bib-0070","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejhf.114","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT","volume":"16","author":"Komajda","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0071","doi-asserted-by":"crossref","first-page":"47E","DOI":"10.1016\/j.amjcard.2005.06.005","article-title":"An approach to heart failure and diabetes mellitus","volume":"96","author":"Fonarow","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0072","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0073","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0074","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ahj.2004.07.005","article-title":"Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure","volume":"149","author":"Smoke","year":"2005","journal-title":"Am Heart J"},{"key":"2026011721200231400_ejhf902-bib-0075","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.347","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial","volume":"17","author":"Komajda","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0076","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ejheart.2004.03.011","article-title":"Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe","volume":"6","author":"Muntwyler","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0077","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-005-0939-0","article-title":"Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study","volume":"61","author":"Maison","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"2026011721200231400_ejhf902-bib-0078","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11897-014-0186-8","article-title":"Polypharmacy in heart failure patients","volume":"11","author":"Mastromarino","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"2026011721200231400_ejhf902-bib-0079","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ejhf.121","article-title":"Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial","volume":"16","author":"D\u00fcngen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0080","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","article-title":"Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study","volume":"15","author":"Tavazzi","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0081","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ejhf.258","article-title":"Twenty-four-hour heart lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy","volume":"17","author":"B\u00f6hm","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0082","first-page":"354","article-title":"Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","volume":"17","author":"Heart rate variability","year":"1996","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0083","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/eurjhf\/hft072","article-title":"Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure","volume":"15","author":"Reil","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0084","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00392-013-0584-z","article-title":"Severity of cardiac impairment in the early stage of community-acquired sepsis determines worse prognosis","volume":"102","author":"Wilhelm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0300-9572(86)90068-7","article-title":"Ultimate survival from septic shock","volume":"14","author":"Azimi","year":"1986","journal-title":"Resuscitation"},{"key":"2026011721200231400_ejhf902-bib-0086","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"Morelli","year":"2013","journal-title":"JAMA"},{"key":"2026011721200231400_ejhf902-bib-0087","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.CCM.0000150028.64264.14","article-title":"Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with high risk of cardiac complications","volume":"33","author":"Sander","year":"2005","journal-title":"Crit Care Med"},{"key":"2026011721200231400_ejhf902-bib-0088","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00392-012-0516-3","article-title":"Ivabradine: potential clinical applications in critically ill patients","volume":"102","author":"De Santis","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0089","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/STROKEAHA.110.598607","article-title":"Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice","volume":"42","author":"Custodis","year":"2011","journal-title":"Stroke"},{"key":"2026011721200231400_ejhf902-bib-0090","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/eurheartj\/ehs250","article-title":"Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke","volume":"33","author":"B\u00f6hm","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0091","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijcard.2014.07.001","article-title":"Heart rate on admission independently predicts in-hospital mortality in acute ischemic stroke patients","volume":"176","author":"Erdur","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0092","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1161\/STROKEAHA.111.628586","article-title":"Effects of 24-hour blood pressure and heart rate recorded with ambulatory blood pressure monitoring on recovery from acute ischemic stroke","volume":"42","author":"Tomii","year":"2011","journal-title":"Stroke"},{"key":"2026011721200231400_ejhf902-bib-0093","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/ene.13115","article-title":"Impact of heart rate on admission on mortality and morbidity in acute ischaemic stroke patients\u2014results from VISTA","volume":"23","author":"Nolte","year":"2016","journal-title":"Eur J Neurol"},{"key":"2026011721200231400_ejhf902-bib-0094","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/STROKEAHA.115.012382","article-title":"Admission heart rate predicts poor outcomes in acute intracerebral hemorrhage: the intensive blood pressure reduction in acute cerebral hemorrhage trial studies","volume":"47","author":"Qiu","year":"2016","journal-title":"Stroke"},{"key":"2026011721200231400_ejhf902-bib-0095","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/ene.13122","article-title":"Heart rate as emerging risk indicator in stroke\u2014the beat goes on","volume":"23","author":"B\u00f6hm","year":"2016","journal-title":"Eur J Neurol"},{"key":"2026011721200231400_ejhf902-bib-0096","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HJH.0b013e3282f05c8a","article-title":"Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH","volume":"26","author":"B\u00f6hm","year":"2008","journal-title":"J Hypertens"},{"key":"2026011721200231400_ejhf902-bib-0097","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/eurheartj\/ehp124","article-title":"Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients","volume":"30","author":"B\u00f6hm","year":"2009","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0098","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/joim.12333","article-title":"Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies","volume":"278","author":"B\u00f6hm","year":"2015","journal-title":"J Intern Med"},{"key":"2026011721200231400_ejhf902-bib-0099","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: results of the Massachusetts Make Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2026011721200231400_ejhf902-bib-0101","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/heart.89.3.251","article-title":"Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator","volume":"89","author":"Solomon","year":"2003","journal-title":"Heart"},{"key":"2026011721200231400_ejhf902-bib-0102","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1742-1241.2006.01274.x","article-title":"Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients","volume":"61","author":"Baumh\u00e4kel","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2026011721200231400_ejhf902-bib-0103","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/2047487313494835","article-title":"Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients","volume":"21","author":"Kratz","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1183\/09031936.00072212","article-title":"Resting heart rate is a predictor of mortality in COPD","volume":"42","author":"Jensen","year":"2013","journal-title":"Eur Respir J"},{"key":"2026011721200231400_ejhf902-bib-0105","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4187\/respcare.01485","article-title":"Cardiopulmonary rehabilitation enhances heart rate recovery in patients with COPD","volume":"57","author":"Georgiopoulou","year":"2012","journal-title":"Respir Care"},{"key":"2026011721200231400_ejhf902-bib-0106","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijcard.2013.10.068","article-title":"Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study","volume":"170","author":"Tavazzi","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0107","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/eurjhf\/hfs009","article-title":"Clinical characterictics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF","volume":"14","author":"Mentz","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00392-013-0541-x","article-title":"Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?","volume":"102","author":"Correale","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0109","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00392-012-0437-1","article-title":"Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension","volume":"101","author":"Correale","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0110","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cardfail.2011.04.011","article-title":"Impact of medication nonadherence on hospitalizations and mortality in heart failure","volume":"17","author":"Fitzgerald","year":"2011","journal-title":"J Card Fail"},{"key":"2026011721200231400_ejhf902-bib-0111","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0149-2918(98)80139-2","article-title":"Predictors of medication adherence in the elderly","volume":"20","author":"Balkrishnan","year":"1998","journal-title":"Clin Ther"},{"key":"2026011721200231400_ejhf902-bib-0112","first-page":"1007","article-title":"What puts heart failure patients at risk for poor medication adherence?","volume":"8","author":"Knafl","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"2026011721200231400_ejhf902-bib-0113","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cardfail.2013.03.010","article-title":"Medication adherence, depressive symptoms, and cardiac event-free survival in patients with heart failure","volume":"19","author":"Wu","year":"2013","journal-title":"J Card Fail"},{"key":"2026011721200231400_ejhf902-bib-0114","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.493","article-title":"Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT","volume":"18","author":"B\u00f6hm","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/oxfordjournals.aje.a113213","article-title":"Heart rate: a risk factor for cancer?","volume":"114","author":"Persky","year":"1981","journal-title":"Am J Epidemiol"},{"key":"2026011721200231400_ejhf902-bib-0116","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0895-4356(00)00353-X","article-title":"Pulse pressure and heart rate: Independent risk factors for cancer?","volume":"54","author":"Thomas","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2026011721200231400_ejhf902-bib-0117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021310","article-title":"Heart rate and risk of cancer death in healthy men","volume":"6","author":"Jouven","year":"2011","journal-title":"PLoS One"},{"key":"2026011721200231400_ejhf902-bib-0118","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.670","article-title":"Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0119","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"2026011721200231400_ejhf902-bib-0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"2026011721200231400_ejhf902-bib-0121","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026011721200231400_ejhf902-bib-0122","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","article-title":"Meta-analysis of the effects of beta blocker on survival time in cancer patients","volume":"140","author":"Choi","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026011721200231400_ejhf902-bib-0123","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1200\/JCO.2012.43.9190","article-title":"Use of \u03b2-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study","volume":"31","author":"S\u00f8rensen","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026011721200231400_ejhf902-bib-0124","doi-asserted-by":"crossref","first-page":"628","DOI":"10.18632\/oncotarget.197","article-title":"Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival","volume":"1","author":"Powe","year":"2010","journal-title":"Oncotarget"},{"key":"2026011721200231400_ejhf902-bib-0125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.689","article-title":"Heart rate: from heart failure to chronic diseases and cancer. Is there a role for supportive care by heart rate reduction?","volume":"19","author":"B\u00f6hm","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721200231400_ejhf902-bib-0126","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0127","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.amjcard.2015.09.029","article-title":"Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial)","volume":"116","author":"B\u00f6hm","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026011721200231400_ejhf902-bib-0128","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(08)61172-1","article-title":"BEAUTIFUL results\u2014the slower, the better?","volume":"372","author":"Reil","year":"2008","journal-title":"Lancet"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/10\/1230\/66327818\/eurjhf_19_10_1230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/10\/1230\/66327818\/eurjhf_19_10_1230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:22:29Z","timestamp":1768702949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/10\/1230\/8418516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":128,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,6,19]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.902","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727730829.793535442","asserted-by":"object"}]},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,6,19]]}}}